Hypothesis

Gut‑microbiome‑derived indole‑3‑propionic acid (IPA) activates the nuclear receptor PXR, which transcriptionally reprograms the cellular quality‑control machinery to favor sequestration of aggregation‑prone proteins into the IPOD (insoluble protein deposit) compartment rather than the toxic JUNQ (juxtanuclear quality control) compartment. This shift reduces chaperone sequestration, limits proteotoxic stress, and extends cellular lifespan.

Mechanistic Rationale

• IPA is a high‑affinity ligand for PXR [(https://pmc.ncbi.nlm.nih.gov/articles/PMC12610759/)]. PXR activation induces expression of Phase‑I/II detox enzymes and, unexpectedly, of the autophagy adaptor p62/SQSTM1 and the histone deacetylase HDAC6, both known to promote aggresome formation and IPOD‑like sequestration [(https://pmc.ncbi.nlm.nih.gov/articles/PMC9156751/) [1]].
• Increased p62 and HDAC6 activity accelerates the maturation of liquid‑liquid phase‑separated condensates into a solid, IPOD‑state that is spatially sequestered away from the juxtanuclear region where Hsp70 is enriched. Consequently, Hsp70 remains available for refolding nascent polypeptides, preventing the chaperone‑trapping phenomenon observed in JUNQ [(https://www.pnas.org/doi/10.1073/pnas.1205829109)].
• In neurons, microbial IPA crosses the blood‑brain barrier and activates neuronal PXR, thereby biasing tau or α‑synuclein aggregates toward IPOD. This protects synaptic function despite overall aggregation load, aligning with observations that IPOD localization of SOD1^G93A^ rescues viability [(https://pmc.ncbi.nlm.nih.gov/articles/PMC4050583/) [2]].
• Aging‑associated decline in microbial IPA production (due to dysbiosis) reduces PXR signaling, tipping the balance toward JUNQ‑type aggregates that sequester Hsp70 and exacerbate proteostasis failure [(https://pmc.ncbi.nlm.nih.gov/articles/PMC3501694/), (https://pmc.ncbi.nlm.nih.gov/articles/PMC9909609/)].

Testable Predictions

1. Pharmacological – Treating aged C. elegans or mouse models with IPA (or a potent PXR agonist) will increase the proportion of insoluble SOD1^G93A^, tau, or α‑synuclein found in IPOD (detected by filter‑trap assay combined with subcellular fractionation) and decrease co‑localization with Hsp70 in JUNQ.
2. Genetic – Neuron‑specific knockout of PXR will abolish IPA‑mediated IPOD enrichment and accelerate age‑dependent motility decline, even if IPA levels are high.
3. Metabolomic – Germ‑free mice colonized with an IPA‑producing bacterial strain will show higher neuronal IPA, increased PXR target gene expression (Cyp3a11, p62, HDAC6), and reduced JUNQ‑associated ubiquitinated species compared with colonized controls.
4. Falsification – If IPA treatment fails to alter aggregate subcellular distribution or does not improve lifespan/healthspan under conditions where PXR is intact, the hypothesis is refuted.

Potential Implications

Linking a microbiome metabolite to the spatial decision between toxic and protective aggregation reframes protein deposits as a regulable sink rather than a static end‑point. It suggests that dietary or probiotic strategies aimed at boosting colonic IPA could preserve proteostasis by enhancing IPOD capacity, offering a tractable avenue to mitigate neurodegenerative disease where JUNQ‑like pathology predominates.